NEW YORK ( TheStreet) -- Cepheid (Nasdaq: CPHD) hit a new 52-week high Wednesday as it is currently trading at $41.64, above its previous 52-week high of $41 with 189,853 shares traded as of 9:50 a.m. ET. Average volume has been 775,600 shares over the past 30 days.

Cepheid has a market cap of $2.4 billion and is part of the technology sector and electronics industry. Shares are up 66.3% year to date as of the close of trading on Tuesday.

Cepheid, a molecular diagnostics company, engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company has a P/E ratio of 946, equal to the average electronics industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
  • Practice your CPHD trading strategies and win cash in our stock game.

TheStreet Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full Cepheid Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird

Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird

Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal

Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Jim Cramer's 'Mad Money' Recap: These Stocks Will Rise, Whatever the Fed Does

Jim Cramer's 'Mad Money' Recap: These Stocks Will Rise, Whatever the Fed Does